Endovascular technologies and reconstructive interventions on profound femoral artery at revascularization of multilevel stenotic-occlusive process of infrainguinal arterial channel

Introduction. Number of patients with obliterating lesions of the aorta and main arteries of the lower extermities has been steadily increasing every year. When choosing the scope of surgical treatment all the features of the multilevel stenotic-occlusive process of the infrainguinal arterial bed should be taken into account.Purpose. To improve the results of revascularization of the infrainguinal arterial bed by applying surgical intervention on profound femoral artery and endovascular methods to restore permeability of the outflow arteries.Materials and methods. The work is based on the results of examination and surgical treatment of 264 patients with stenotic-occlusive process of the infrainguinal arterial bed. There were four groups of patients. The basis of revascularization interventions on the infranguinal artery was shunt surgery. Bypass surgery was performed using a reverse autovein. The combined shunt was used for localization of the distal anastomosis at the level of the popliteal, shin arteries, tibioperinel trunk.Results. In atherosclerotic stenotic-occlusive lesions of the infrainguinal arterial bed of the lower extremity, the volume of surgical treatment depends on the level of the occlusive process, the functional state of the PFA and the blood flow pathways. And the method of surgical intervention in shunt interventions is determined by the type of distal lesion and the level of imposition of distal and proximal anastomoses.Conclusion. The use of endovascular methods of revascularization and reconstructive interventions on PFA in combination with femoral-distal shunt operations contributes to good and satisfactory results of surgical treatment of stenotic-occlusive processes of the infrainguinal arterial bed.</p

Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial

BACKGROUND: Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not ideal. We aimed to assess non-inferiority of idrabiotaparinux, a reversible longlasting indirect inhibitor of activated factor X, to warfarin in patients with acute symptomatic pulmonary embolism. METHODS: In our randomised, double-blind, double-dummy, non-inferiority trial, we enrolled adults with objectively documented acute symptomatic pulmonary embolism attending 291 centres in 37 countries. We excluded patients who were pregnant, had active bleeding, kidney failure, or malignant hypertension, or were at high risk of death, bleeding, or adverse reactions to study drugs. We randomly allocated patients to receive 5-10 days' enoxaparin 1\ub70 mg/kg twice daily followed by subcutaneous idrabiotaparinux (starting dose 3\ub70 mg) or adjusted-dose warfarin (target international normalised ratio 2\ub70-3\ub70); regimens lasted 3 months or 6 months dependent on clinical presentation. Block randomisation was done with a central interactive computerised system, stratified by study centre and intended treatment duration. The primary efficacy outcome was recurrent venous thromboembolism at 99 days after randomisation. We estimated the odds ratio and 95% CI with a Mantel-Haenzsel \u3c7(2) analysis (non-inferiority margin 2\ub70) in the intention-to-treat population. The main safety outcome was clinically relevant bleeding (major or non-major) in all patients at day 99. This study is registered with ClinicalTrials.gov, number NCT00345618. FINDINGS: Between Aug 1, 2006, and Jan 31, 2010, we enrolled 3202 patients aged 18-96 years. 34 (2%) of 1599 patients randomly allocated to receive enoxaparin-idrabiotaparinux and 43 (3%) of 1603 patients randomly allocated to receive enoxaparin-warfarin had recurrent venous thromboembolism (odds ratio 0\ub779, 95% CI 0\ub750-1\ub725; p(non-inferiority)=0\ub70001). 72 (5%) of 1599 patients in the enoxaparin-idrabiotaparinux group and 106 (7%) of 1603 patients in the enoxaparin-warfarin group had clinically relevant bleeding (0\ub767, 0\ub749-0\ub791; p(superiority)=0\ub70098). We noted similar differences in outcomes in those patients treated to 6 months. INTERPRETATION: Idrabiotaparinux could provide an attractive alternative to warfarin for the long-term treatment of pulmonary embolism, and seems to be associated with reduced bleeding